drugset / Trial / NCT04459585

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

NCT04459585

Phase 0 Completed 20 enrolled Daiichi Sankyo
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to investigate the one-way drug-drug interaction potential of quizartinib on dabigatran etexilate in healthy adult participants.

Timeline

Start
2020-08-28
Primary completion
2020-10-20
Completion
2020-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg Oral
Subject Quizartinib Small molecule 60 mg Oral

Indications

No indication recorded.